Type 1 Diabetes Autoantibody Screening
To align the type 1 diabetes (T1D) community with a shared goal, SPARC partnered with the Leona M. and Harry D. Helmsley Charitable Trust to develop an implementation road map that balances short- and long-term impact. The plan and the 2022 Report Update build on existing screening efforts to accelerate tools and guidelines, while guiding research to demonstrate the benefits of general population screening, critical for shaping national screening policies.
Our Work
Type 1 Diabetes Autoantibody Screening: A Roadmap for Pediatric Policy ImplementationÂ
This report, developed by SPARC with support from the Helmsley Charitable Trust, presents a comprehensive road map to implement population-wide T1D screening, outlining four primary goals and 16 actionable steps.
Type 1 Diabetes Autoantibody Screening Implementation Roadmap: 2022 REPORT UPDATE
In response to rapid progress in the field, SPARC released an update to its 2021 road map for implementing T1D autoantibody screening in the general population. Based on interviews, public input, and a stakeholder session, the report highlights current efforts, evaluates progress, and identifies key areas requiring continued collaboration to advance widespread screening.
